Table 3.

Increases in CD4+ T Cells after IL-2 Therapy; Numbers of CD25⁺ CD4⁺ T Cells

scIL-2 dose	Baseline	After 3 Cycles	Change
7.5 MIU	16.6 ± 13.0	315.4 ± 196.7	299 ± 199
1.5 MIU	12.8 ± 13.6	110.6 ± 103.9	98 ± 111
Control	22.3 ± 15.6	52.3 ± 15.3	30 ± 23

Numbers of CD25⁺ CD4⁺ T cells at baseline and after 3 cycles of scIL-2 therapy (week 24). The high dose IL-2 produced the greatest increase in CD25 numbers after scIL-2 administration. The high group had 4, the low group has 5 and none had 3.